Tp‐e and (Tp‐e)/QT ratio as a non‐invasive risk factors for malignant ventricular arrhythmia in patients with idiopathic ventricular premature complexes

Donghua Zhao,Bo Liang,Jian Peng,Liangyu Tang,Rongbin Su,Lingli Luo,Bin Deng,Shuyuan Wang
DOI: https://doi.org/10.1002/jcla.23636
IF: 3.124
2020-12-17
Journal of Clinical Laboratory Analysis
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>To evaluate the role of Tp‐e and (Tp‐e)/QT ratio in differentiating benign ventricular premature complex (VPC) and malignant polymorphic ventricular tachycardia (PVT).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>From January 2017 to December 2017, patients with documented polymorphic ventricular tachycardia (PVT) or ventricular fibrillation (VF) were consecutive included and classified as PVT/VF group. Sixty age‐ and sex‐matched healthy individuals were recruited as comparative control and subdivided into non‐VPC and VPC group. Clinical characteristics and Tp‐e and Tp‐e/QT ratio between the three groups were compared.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Tp‐e and (Tp‐e)/QT ratio were significantly higher in patients of PVT/VF group compared with the other two groups (<i>P</i> &lt; .001). Episodes of syncope were more frequent in patients with PVT/VF (<i>P &lt; </i>.05). The sensitivity and specificity of a Tp‐e interval ≥86 ms for malignant arrhythmias triggered by VPCs were 88% and 66%, respectively, while the sensitivity and specificity of the Tp‐e/QT ratio ≥0.24 were 82% and 70%, respectively. Five patients complained recurrence of syncope in the PVT/VF group and 1 patient died with mean follow‐up of 18 months. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Tp‐e interval and the Tp‐Te/QT ratio is significantly increased in patients with PVT/VF and may be used as a novel non‐invasive marker of differentiating malignant and benign VPC.</p></section>
medical laboratory technology
What problem does this paper attempt to address?